EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

First-line treatment of TAFRO syndrome with rituximab: a case report and literature review

Salar Servati, Ida Mohammadi, Shahryar Rajai Firouzabadi

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06327-9 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Salar Servati und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Taleghani General Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. saliser999@gmail.com. Hauptthemen laut MEDLINE: Rituximab, Castleman Disease. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TAFRO syndrome, a rare variant of Castleman's disease, is characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly. First-line treatments typically include immunosuppressive therapies such as cyclosporine A and tocilizumab. However, the use of rituximab as a first-line therapeutic agent remains under-reported. Here, we present the case of a 38-year-old female patient who initially exhibited lymphadenopathy and gradually developed the full spectrum of symptoms associated with TAFRO syndrome during her hospital stay. Rituximab, supplemented by prednisolone, was administered as the primary treatment. Over a follow-up period of five months, the patient's condition improved significantly, suggesting a positive therapeutic response. This case highlights the potential efficacy of rituximab as an alternative first-line therapy for TAFRO syndrome, offering a possible treatment option where standard therapeutic agents may not be available, suitable or effective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabCastleman DiseaseHumansFemaleAdultThrombocytopeniaPrednisoloneFever

Stichwörter der Autor:innen

Castleman’s diseaseRituximabTAFRO syndrome

Substanzen

RituximabPrednisolone

Autor:innen und Institutionen

  • Department of Hematology, Taleghani General Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. saliser999@gmail.com.
  • School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. idamohammadi2000@gmail.com.
  • School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Servati, S., Mohammadi, I., & Rajai Firouzabadi, S. (2025). First-line treatment of TAFRO syndrome with rituximab: a case report and literature review. Annals of Hematology. https://doi.org/10.1007/s00277-025-06327-9

Vancouver

Servati S, Mohammadi I, Rajai Firouzabadi S. First-line treatment of TAFRO syndrome with rituximab: a case report and literature review. Annals of Hematology. 2025. doi:10.1007/s00277-025-06327-9

BibTeX
@article{Servati2025,
  author = {Servati, Salar and Mohammadi, Ida and Rajai Firouzabadi, Shahryar},
  title = {First-line treatment of TAFRO syndrome with rituximab: a case report and literature review},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06327-9}
}
Kostenlos starten →